We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
GlaxoSmithKline (GSK) said it plans to manufacture 1 billion doses of its vaccine adjuvant next year to support multiple COVID-19 vaccine candidates. Read More
Maryland-based Novavax is expanding its manufacturing capacity for its COVID-19 vaccine candidate by acquiring a manufacturer in the Czech Republic as drugmakers rush to prepare for the global deployment of a successful vaccine. Read More
Bangladesh-based Beximco Pharmaceuticals has become the first company to launch a generic version of Gilead Sciences’ remdesivir for treating COVID-19. Read More
TriNetX is partnering with the FDA’s Sentinel Operations Center at the Harvard Pilgrim Health Care Institute (HPHCI) to monitor priority drugs used for treating hospitalized COVID-19 patients. Read More
In a surprise move, HHS has awarded a new Virginia-based company a $354 million contract to produce active pharmaceutical ingredients (APIs) and finished drugs to create a new Strategic Active Pharmaceutical Ingredients Reserve. Read More
AstraZeneca will manufacture up to 30 million doses of Oxford University’s coronavirus vaccine by September if trials show it to be effective — and 100 million doses for global deployment by year’s end, the UK’s Secretary of State for Business Alok Sharma has announced. Read More
To make remdesivir available to COVID-19 patients in low-income nations, Gilead Sciences has signed non-exclusive licensing agreements with five generic drugmakers to allow them to manufacture and sell the antiviral. Read More
About 28 million doses of hydroxychloroquine were distributed from the Strategic National Stockpile last month and states are wondering what to do with their excess supply since studies have cast doubt on the drug’s benefit as a COVID-19 treatment. Read More